What is Chembio Diagnostics?
Chembio Diagnostics, Inc., headquartered in Hauppauge, New York, is a developer, manufacturer, marketer, and licensor of rapid point-of-care (POC) diagnostic tests. The company specializes in detecting infectious diseases, offering a range of rapid tests for HIV and syphilis. Its product line includes the STAT-PAK and SURE CHECK brands, as well as the Dual Path Platform (DPP) technology, which provides visually interpreted results for HIV 1/2 antibodies and multiplex testing for HIV and syphilis. Chembio also offers tests for Hepatitis-C and has established collaborations to develop POC diagnostic tests for traumatic brain injury and specific types of cancer. The company serves medical laboratories, hospitals, public health entities, non-governmental organizations, medical professionals, and retail establishments globally.
How much funding has Chembio Diagnostics raised?
Chembio Diagnostics has raised a total of $31M across 1 funding round:
Share Placement
$31M
Share Placement (2020): $31M, investors not publicly disclosed
What's next for Chembio Diagnostics?
The recent major strategic investment positions Chembio Diagnostics for significant growth and further development of its innovative POC diagnostic solutions. This capital infusion is expected to accelerate the company's market penetration and support ongoing research and development initiatives, particularly in expanding its test offerings for infectious diseases and other critical health conditions. The company's focus on strategic partnerships and its established product lines suggest a continued emphasis on expanding its global reach and solidifying its presence in the competitive diagnostics sector.
See full Chembio Diagnostics company page
